

NATCO files ANDA for Oseltamivir, (Tamiflu ®)
ties up with Alvogen, gets First to File Status



Hyderabad , February 9th, 2011

The Hyderabad based **NATCO** Pharma Limited is pleased to announce the acceptance of its Abbreviated New Drug Application for the generic version of Oseltamivir Phosphate capsules.

Oseltamivir Phosphate is used in the treatment of bird and swine-flu infections. Sold under the brand name Tamiflu®, the product clocked global annual sales in the region of US \$ 1 Billion.

NATCO has tied up with the Luxemburg based Alvogen IPCO S.a.r.l., for marketing and sale of Oseltamivir Phosphate in the USA.

NATCO is the "first applicant" to file an ANDA for the generic version of Tamiflu® and, should the ANDA be approved, may be entitled to 180 days of generic market exclusivity.

Forwarded for favor of publication

For NATCO Pharma Limited


Dr. Bhaskara Narayana. P.
Director & Chief Financial Officer